Servier marks 40 years in Brazil with plans for new meds and investment

7 April 2016

Privately-held Servier has marked 40 years of operations in Brazil by announcing plans to launch 15 new medicines not only for diabetes, but also for cancer and cardiovascular diseases – the country’s second biggest killers.

The new drug launches to take place over the next five years are part of a series of investments in the South American country revealed by the French pharma company.

With a factory producing 500 million tablets per year, and a research and development center where more than 20 clinical trials have already been performed, the company is increasingly investing in research and supporting social projects alongside Brazilian medical societies and public research institutions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK